



Cryofocus Medtech (Shanghai) Co., Ltd.
康禮生物科技（上海）股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(於中華人民共和國註冊成立的股份有限公司)
(Stock Code 股份代號: 6922)

April 30, 2025

Dear registered shareholder(s),

Reminder letter regarding the Arrangement of Electronic Dissemination of Corporate Communications

With reference to the notification letter dated March 14, 2024 titled "Arrangement of Electronic Dissemination of Corporate Communications", Cryofocus Medtech (Shanghai) Co., Ltd. (the "**Company**") is writing to remind you that the Company has adopted electronic dissemination of corporate communications (the "**Corporate Communications**"), which mean any documents issued or to be issued by the Company for the information or action of holders of any of its securities, including but not limited to (a) the directors' report, its annual accounts together with a copy of the auditors' report and, where applicable, its summary financial report; (b) the interim report and, where applicable, its summary interim report; (c) a notice of meeting; (d) a listing document; (e) a circular; and (f) a proxy form.

Please note that both the English and Chinese versions of all future Corporate Communications will be available electronically on the website of the Company at www.cryofocus.com and the HKEXnews website at www.hkexnews.hk in place of printed copies.

Solicitation of electronic contact details

Pursuant to Rule 2.07A of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, the Company shall despatch to you by electronic means or by post the Actionable Corporate Communications ^(Note). The Company has not received your email address for the electronic dissemination of Corporate Communications. To ensure timely receipt of the latest Corporate Communications, the Company recommends you provide your email address by scanning your personalized QR code printed on the enclosed reply form (the "**Reply Form**"). Alternatively, you may sign and return the Reply Form to the Company's H Share Registrar (the "**H Share Registrar**"), Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong. **If the Company does not receive a functional email address in your reply, until such time that the functional email address is provided to the H Share Registrar, the Company will send the Actionable Corporate Communications in printed form in the future.**

If you want to receive the Corporate Communications in printed form, please complete the enclosed Reply Form and send it to the H Share Registrar or send an email to cryofocus.ecom@computershare.com.hk specifying your name, address and request to receive the Corporate Communications in printed form. Please note that such instruction shall be valid for one year starting from the receipt date of your instruction and will expire thereafter.

Please be reminded that provision of your correct and effective contact details (including email address and mailing address) to the Company and /or the H Share Registrar is critically important, and any mistakes in such details may result in failure of delivery of the Company's Corporate Communications and/or Actionable Corporate Communications to you timely in the future.

Should you have any queries relating to this letter, please contact the H Share Registrar at (852)2862 8688 during business hours from 9:00 a.m. to 6:00 p.m. (Hong Kong time), Mondays to Fridays, excluding Hong Kong public holidays.

By order of the Board
Cryofocus Medtech (Shanghai) Co., Ltd.
Mr. LI Kejian
Chairman of the Board

Note: Actionable Corporate Communication is any corporate communication that seeks instructions from the Company's securities holders on how they wish to exercise their rights or make an election as the issuer's securities holder.

各位登記股東：

以電子方式發布公司通訊安排的提示信函

根據日期為 2024 年 3 月 14 日有關「以電子方式發布公司通訊之安排」之通知信函所述，康禮生物科技（上海）股份有限公司（「**公司**」）謹此提醒 閣下，公司已採用以電子方式發布公司通訊（「**公司通訊**」）之安排，該公司通訊是指公司為向其任何證券持有人提供資訊或提醒其採取行動而發布或將要發布的任何文件，包括但不限於(a) 董事報告、年度帳目以及審計報告副本以及（如適用）財務摘要報告；(b) 中期報告及（如適用）其中期報告摘要；(c) 會議通知；(d) 上市文件；(e) 通函；和 (f) 委任表格。

請注意，所有未來公司通訊的英文版和中文版將在公司網站 www.cryofocus.com 和披露易網站 www.hkexnews.hk 上提供，以代替印刷本。

徵集電子聯絡資料

根據香港聯合交易所有限公司證券上市規則第 2.07A 條，公司須向 閣下以電子方式或者郵寄方式寄送可供採取行動的公司通訊 ^(附註)。公司尚未收到閣下就接收公司通訊提供電子郵件地址。為確保及時收到最新的公司通訊，公司建議 閣下透過掃描本函隨附之回條（「**回條**」）上列印的 閣下專屬二維碼來提供 閣下的電子郵件地址。或者， 閣下也可以簽署回條並交回公司的 H 股證券登記處（「**H 股證券登記處**」）香港中央證券登記有限公司，地址為香港灣仔皇后大道東 183 號合和中心 17M 樓。如果公司沒有收到 閣下的有效電子郵件地址，直至 H 股證券登記處收到 閣下有效的電子郵件地址前，公司未來將以印刷形式發送可供採取行動的公司通訊。

若 閣下希望收取日後公司通訊之印刷本，請填妥隨附之回條並交予 H 股證券登記處或發送電子郵件至 cryofocus.ecom@computershare.com.hk，並註明 閣下的姓名、地址以及收取公司通訊印刷版的要求。請注意，收取日後公司通訊印刷本之指示由收悉 閣下指示當日起計一年內有效，此後將過期。

公司謹此提醒 閣下，向公司及/或 H 股證券登記處提供 閣下正確及有效的联系方式（包括電子郵件及聯系地址等）至關重要，任何資料錯誤可能導致 閣下無法及時接收公司發布的公司通訊及/或可供採取行動的公司通訊（視實際情況而定）。

如 閣下對本函件有任何疑問，請於辦公時間星期一至五（香港公眾假期除外）上午 9 時正至下午 6 時正（香港時間）期間致電 H 股證券登記處(852)2862 8688 查詢。

承董事會命
康禮生物科技（上海）股份有限公司
董事會主席
李克儉先生

2025 年 4 月 30 日

附註：可供採取行動的公司通訊指任何涉及要求公司的證券持有人指示其擬如何行使其有關證券持有人的權利或作出選擇的公司通訊。



當閣下寄回此回條時，請將郵寄標籤剪貼於信封上。
如在本港投寄，閣下無需支付郵費或貼上郵票。